Other indications for TRT in neuro-oncology, include grade I-III glioma (e.g. radiolabeled SP and anti-EGFR TRT), brain metastasis (e.g. 177Lu]Lu-/[225Ac]Ac-PSMA-617), meningioma (e.g. radiolabelled DOTA-TOC and DOTA-TATE), lymphoma (e.g. [90Y]-ibritumomab tiuxetan) and neuroblastoma (e.g. [131I]iodo-MIBG) 113,114. The gene discussed is FOLH1; the disease is central nervous system cancer.